cefditoren

structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer

Also Known As:

ME 1206; ME-1206; cefditoren, sodium salt, (6R-(3(Z),6alpha,7beta(Z)))-isomer; 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)-1-oxoethyl)amino)-3-((Z)-2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-, (6R,7R)-

Networked: 59 relevant articles (3 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Aguilar, Lorenzo: 6 articles (01/2018 - 08/2007)
2.	Barberán, J: 5 articles (02/2022 - 03/2008)
3.	Giménez, María-José: 5 articles (01/2018 - 08/2007)
4.	Coronel, Pilar: 3 articles (08/2010 - 08/2007)
5.	Coronel, P: 3 articles (06/2009 - 03/2007)
6.	Gimeno, M: 3 articles (06/2009 - 03/2007)
7.	Frei, Christopher R: 2 articles (01/2020 - 01/2019)
8.	Teng, Chengwen: 2 articles (01/2020 - 01/2019)
9.	Wang, Hui: 2 articles (01/2014 - 06/2012)
10.	Barberán, José: 2 articles (01/2012 - 01/2010)

Related Diseases

1.	Respiratory Tract Infections (Respiratory Tract Infection) 03/01/2008 - "Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials." 06/01/2012 - "The aim of this study was to evaluate the in vitro activity of cefditoren and comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections (CARTIs). " 01/01/2010 - "The documented information on cefditoren gleaned from published studies in recent years is an example of the role for an emerging oral antibacterial facing current antibiotic resistance in community-acquired respiratory tract infections." 06/01/2009 - "Safety data from all 13 clinical trials of cefditoren on community acquired respiratory infections were reviewed. " 03/01/2008 - "A pooled analysis of all upper respiratory tract infection studies performed with cefditoren (CDN) was performed. "
2.	Infections 10/01/2008 - "Four patients in the cefditoren group were excluded from the study analyses (2 who were noncompliant [used <80% of the assigned medication] and 2 who developed infection at other sites). " 12/01/2017 - "[Cefditoren: a reality for the treatment of community infections]." 09/25/2012 - "Multivariate analysis demonstrated history of urinary infection in the last two weeks or three months as risk factors for cefditoren resistance. " 06/01/2009 - "Clinical trial data worldwide support the use of cefditoren for infections and species that have been approved by the US Food and Drug Administration (US-FDA). " 06/01/2009 - "Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations."
3.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2014 - "Last, recent findings suggested that cefditoren can be a valid alternative to levofloxacin in outpatients with acute exacerbation of COPD; in this setting a treatment with cefditoren showed to be associated with a significant reduction of some key inflammatory markers involved in epithelial damage, including KL-6 and IL-6." 02/01/2022 - "With these premises, the oral treatment guidelines for mild or moderate COPD-E and CAP in Spain include as first options beta-lactam antibiotics (amoxicillin and amoxicillin-clavulanate and cefditoren), in certain situations associated with a macrolide, and relegating fluoroquinolones as an alternative, except in cases where the presence of Pseudomonas aeruginosa is suspected."
4.	Maxillary Sinusitis 12/01/2001 - "Cefditoren is effective in the management of AECB (in regimens of 400 mg twice daily for 10 days) and acute maxillary sinusitis, pharyngotonsillitis due to S pyogenes, and uncomplicated skin/skin structure infections (in regimens of 200 mg twice daily for 10 days). "
5.	Pneumonia (Pneumonitis) 06/01/2009 - "Overall reported diarrhoea related to cefditoren administration was significantly higher (p < or = 0.001) than comparators (9.9% vs 6.9%) due to the significant difference in the pooled pharyngotonsillitis studies (8.3% vs 3.2%), while no significant differences in others pathologies were found, with 9.4% (with cefditoren) vs 10.3% (with comparators) in the case of community-acquired pneumonia (CAP). " 11/01/2002 - "This study was conducted to examine the efficacy and tolerability of cefditoren in the treatment of community-acquired pneumonia (CAP). " 01/01/2014 - "The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage." 10/16/2010 - "[Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?]." 02/09/2011 - "By relating the in vitro activity of cefditoren (in national and multinational surveillance and against isolates with emerging resistant genotypes/phenotypes) to its pharmacokinetics, the cefditoren pharmacodynamic activity predicting efficacy (in humans, animal models, and in vitro simulations) is analyzed prior to reviewing clinical studies (tonsillopharyngitis, sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia) and the relationship between bacterial eradication and clinical efficacy. "

Related Drugs and Biologics

1.	Levofloxacin (Levaquin)
2.	Interleukin-6 (Interleukin 6)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Cephalosporins (Cephalosporin Antibiotics)
5.	Cefuroxime (Zinacef)
6.	Clavulanic Acid (Potassium Clavulanate)
7.	Amoxicillin (Wymox)
8.	Penicillins (Penicillin)
9.	Fluoroquinolones
10.	Linezolid (Zyvox)

Related Therapies and Procedures

1.	Therapeutics